THIS IS THE NEW AGE OF HEALTHCARE
From genomics to telehealth, from pharma R&D to medical imaging, the companies that are embedding AI into their operating core are separating from the rest. What used to be a futuristic add-on is now table stakes -- and the capital is reallocating with that in mind. But this shift didn’t just happen in a vacuum. It was catalyzed by something bigger: a narrative change. Policy momentum. Political alignment.
Tempus Is Building the Operating System of AI Healthcare
At the center of this shift is $Tempus AI(TEM)$ -- and it’s not just a participant in the AI healthcare boom. It’s the scaffolding beneath it.
Tempus isn’t building tools. It’s building the rails. While most healthtech companies are optimizing a single touchpoint -- a diagnosis here, a recommendation there -- Tempus is embedding itself across the entire ecosystem. From real-time clinical decisions to insurance workflows to pharmaceutical development, it’s not just interfacing with the system -- it’s becoming the system.
What sets Tempus apart isn’t just the volume of data it holds, but how that data is weaponized in the moment care is delivered. Its operating platform plugs directly into oncologist workflows, interpreting genomic data at scale, and feeding those insights back to physicians in time to shift treatment paths in real time. It's decision-making, not documentation. A clinical intelligence layer that lives inside the hospital, not outside it.
But that’s only the beginning. Tempus isn’t just in the business of diagnostics -- it’s building the nervous system of AI-native medicine. Its reach now extends beyond oncology, into cardiovascular disease, neurological disorders, infectious disease, and more. Its datasets aren’t just massive -- they’re multimodal, pulling together pathology, imaging, genomic sequencing, clinical notes, and treatment outcomes into one longitudinal platform. That fusion is what makes the AI models not just accurate, but actionable. It’s not a black box. It’s a map.
This is why Pelosi’s disclosure sent a ripple. This is why investors are suddenly watching D.C. not just for regulation -- but for acceleration. Because if this HHS leadership prioritizes AI adoption and eases the friction around data interoperability and model deployment, companies like Tempus don’t just grow. They become default infrastructure.
$Hims & Hers Health Inc.(HIMS)$ vs $Amazon.com(AMZN)$ Is the Battle for Belonging
Elsewhere, consumer healthcare is undergoing its own version of disruption. $HIMS has rewritten the DTC playbook, scaling faster and with more brand intimacy than anyone thought possible. Now, it faces its biggest test -- not from another startup, but from AMZN. With One Medical’s $9/month Prime membership and a logistics backbone that can deliver healthcare like it delivers packages, Amazon has the infrastructure, the pricing power, and the patience to bleed margin if it means deepening Prime loyalty. It doesn’t need telehealth to be a profit center. It just needs it to be sticky.
And yet, that doesn’t mean Amazon wins.
Because this could very well be a $Spotify Technology S.A.(SPOT)$ vs $Apple(AAPL)$ -- where scale and integration meet their match in identity and trust. Hims isn’t trying to be a utility. It’s a brand. One that consumers choose -- not because it’s bundled, but because it resonates. Because it feels like part of their lifestyle. Their aesthetic. Their voice. That matters in healthcare more than people realize. In a space where trust is everything, cold efficiency doesn’t always win.
Hims has built something that’s defensible not through patents, but through presence. It has created a culture around wellness that feels personal. Retention rates continue to beat expectations. High-margin categories like GLP-1 weight loss and dermatology are expanding. And while customer acquisition costs are rising across the board, Hims still converts better than most -- because its brand affinity bends the funnel. It doesn’t just acquire customers. It earns them.
That’s the tension playing out now. Amazon brings distribution. Hims brings emotion. One optimizes for scale. The other, for belonging. And in a category like health, where identity and trust compound over time, that could be the difference between being a feature -- and being the destination.
Recursion Is the AI Discovery Engine Behind the Next Pharma Era
$Recursion Pharmaceuticals, Inc.(RXRX)$ is doing something even more radical: it isn’t adapting to the AI era -- it’s rebuilding pharma for it. Traditional drug discovery has always been a slow grind through a swamp of trial-and-error -- decades of benchwork, billions in sunk costs, and a pipeline defined more by attrition than acceleration. Recursion is throwing that playbook out. Not to digitize it. To replace it. What they’re building isn’t a biotech company that uses AI. It’s an AI company that happens to discover drugs.
Their platform is powered by a library of over 23 petabytes of biological and chemical data, gathered and structured through automated high-throughput experiments. One that their proprietary models are trained to interpret at a scale and speed no human team could replicate. Instead of testing one drug for one condition, Recursion scans millions of compound-disease interactions in parallel, surfacing novel candidates that would never have made it past a traditional screening funnel. It’s not acceleration. It’s compression -- turning a multi-year process into a multi-week output.
And it’s not just theory. Big pharma is buying in. Their partnerships with Bayer, Roche, and others aren’t headline bait. They’re validation. Not just of the tech — but of the model. A model where Recursion doesn’t just license compounds, but owns the infrastructure that finds them. That’s what makes the story different. Because Recursion’s value isn’t bound to a single drug. It’s tied to a repeatable system that can manufacture insights on demand. If Tempus is building the diagnostic OS of healthcare, Recursion is building its discovery engine.
The new era of healthcare isn’t coming. It’s already here -- running in the background of hospital systems, embedded in clinical decisions, reshaping how drugs are discovered and how care is delivered. It’s not loud. It’s not headline-grabbing. It’s infrastructural. Relentless. Inevitable.
Image
Open a CBA today and enjoy privileges of up to SGD 20,000 in trading limit with 0 commission. Trade SG, HK, US stocks as well as ETFs unlimitedly!
For whom haven't open CBA can know more from below:
Find out more here：
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
